New blood thinning agent approved for GPs in Scotland

Rivaroxaban for DVT and for stroke prevention in AF has been approved by the Scottish Medicines Consortium (SMC), widening treatment options for GPs in Scotland.

DVT: The thrombus (abnormal clot, white) is blocking the flow of blood (red) in the vein (Photograph: SPL)
DVT: The thrombus (abnormal clot, white) is blocking the flow of blood (red) in the vein (Photograph: SPL)

Marketed as Xarelto by Bayer and licenced in the UK, rivaroxaban works by blocking Factor Xa, a blood clotting agent.

The SMC accepted rivaroxaban for the treatment for DVT and prevention of recurrent DVT and pulmonary embolism following acute DVT in adults.

It also accepted the anticoagulant for limited use in the prevention of stroke and systemic embolism in adults with non-valvular AF and at least one risk factor. Use is restricted to patients who have poor INR control despite compliance with coumarin anticoagulant, and to patients who are allergic to or unable to tolerate coumarin anticoagulants.

Evidence considered by the consortium found rivaroxaban worked as well as standard therapy, but showed additional bleeding against placebo. SMC said it approved the drug because it offers 'value for money'.

The drug was previously accepted by SMC for prevention of venous thromboembolism in adults who undergo hip and knee surgery in 2008.

NICE is also considering rivaroxaban for preventing stroke and systemic embolism in AF. But it held back from recommending the drug in draft guidance issued in January.

The institute said the relative effectiveness of rivaroxaban compared with warfarin had been 'overestimated' for the UK population, and called on Bayer to submit further evidence.

NICE will issue its final guidance by May.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

UK COVID-19 vaccination programme tracker

UK COVID-19 vaccination programme tracker

GPs across the UK are playing a leading role in the largest-ever NHS vaccination...

GP-led sites behind almost three quarters of COVID-19 jabs in England

GP-led sites behind almost three quarters of COVID-19 jabs in England

GP-led vaccination sites have delivered nearly three quarters of COVID-19 vaccine...

GPs should ignore calls to throw away usable COVID-19 vaccine, says RCGP

GPs should ignore calls to throw away usable COVID-19 vaccine, says RCGP

Suggestions that vaccination sites should throw away usable doses of COVID-19 vaccine...

GPs urged to use influence to dispel COVID-19 vaccine myths and boost BAME uptake

GPs urged to use influence to dispel COVID-19 vaccine myths and boost BAME uptake

GPs have been encouraged to use their ‘huge influence’ to bust misinformation around...

Six in 10 over-80s vaccinated against COVID-19 as figures expose regional variation

Six in 10 over-80s vaccinated against COVID-19 as figures expose regional variation

Six in 10 people aged over 80 in England received a first dose of COVID-19 vaccine...

Summary of changes to the GP contract 2021/22

Summary of changes to the GP contract 2021/22

The BMA and NHS England have agreed minor changes to the GP contract for 2021/22....